Top

Fennec Pharmaceuticals Inc.

TSX Exchange | Aug 7, 2020, 11:09 PM EDT | Real-time price

FRX $ 12.00 RT
CHANGE
0.51 (4.4386%)
VOLUME
600
Day Low: 11.52
Day High: 12.07
Detailed Quote
Open: 11.52
High: 12.07
Beta: 0.3148
Listed Shares Out.1: 25,356,034
Total Shares (All Classes)2: 25,356,034
Prev. Close: 11.49
Low: 11.52
VWAP: 11.902
Market Cap1: 304,272,408
Market Cap (All Classes)2*: 304,272,408
Dividend: N/A
Div. Frequency: N/A
P/E Ratio: N/A
EPS: -0.83
Yield: N/A
Ex-Div Date: N/A
P/B Ratio: 15.00
Exchange: TSX

(1) Number based only on listed classes of shares.

(2) Number sourced from third party data provider. For the most up to date information, please refer to the company's financial documents.

*Market Capitalization is based on Total Shares Outstanding for all share classes for the company. Convertible bonds and employee stock options that would otherwise be included in the Diluted Shares amount included in a company's filings/financials are not included.

Description

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children. More

News Headlines for Fennec Pharmaceuticals Inc.
Research
News Headlines for Fennec Pharmaceuticals Inc.
Last 25 Trades
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. View delay times for all exchanges. Market Data powered by QuoteMedia, Fundamentals by Morningstar. See the QuoteMedia Terms of Use.